Associated Papers
Combining Molecular Dynamics and Machine Learning to Predict Drug Resistance Causing Variants of BRAF in Colorectal Cancer.
Xie L et al.
Molecules (basel, Switzerland), 2025
Management of asynchronous multifocal adult glioblastoma with loss of BRAFV600E -mutant clonality: a case report.
Haile H et al.
Acta Neuropathologica Communications, 2025
BRAF - a tumour-agnostic drug target with lineage-specific dependencies.
Hanrahan AJ et al.
Nature Reviews. Clinical Oncology, 2024
BRAF Mutations in CNS Tumors-Prognostic Markers and Therapeutic Targets.
Muniz TP et al.
Cns Drugs, 2023
Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma.
Schreck KC et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research, 2021
Targeted Therapy for BRAF Mutant Brain Tumors.
Rayi A et al.
Current Treatment Options in Oncology, 2021
Melanoma: Double BRAF mutation, double chance to treat?
Proietti I et al.
Dermatologic Therapy, 2020
BRAF mutation and its inhibitors in sarcoma treatment.
Liu H et al.
Cancer Medicine, 2020
CRISPR Screens Identify Essential Cell Growth Mediators in BRAF Inhibitor-resistant Melanoma.
Li Z et al.
Genomics, Proteomics & Bioinformatics, 2020
Challenges of targeting BRAF V600E mutations in adult primary brain tumor patients: a report of two cases.
Smith-Cohn M et al.
Cns Oncology, 2019
BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors.
Schreck KC et al.
Cancers, 2019
A Secondary Mutation in BRAF Confers Resistance to RAF Inhibition in a BRAFV600E-Mutant Brain Tumor.
Wang J et al.
Cancer Discovery, 2018
BRAF Dimerization: An Underlying Resistance Mechanism in Low-Grade Pediatric Gliomas.
Romano G et al.
Cancer Discovery, 2018
Select a paper to view details